Peptides
SS-31 (Elamipretide)
SS-31 (Elamipretide) is a mitochondria-targeted peptide studied in cellular energy research. Below, we compare vendors currently stocking research-grade SS-31 — not just a single sales page.
SS-31 (Elamipretide) is a mitochondria-targeted peptide studied in cellular energy research. Below, we compare vendors currently stocking research-grade SS-31 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 UK SarmsBest Value |
£49.99 | Third-party COA | Auto-applied | Buy Here → |
 American Peptides |
From $70.00 | Third-party COA | Buy Here → | |
 Amino Vault |
$187.00 | Third-party COA | Buy Here → |
SS-31 (Elamipretide) is a synthetic, mitochondria-targeted tetrapeptide developed by researchers Hazel Szeto and Peter Schiller. It is among the more clinically advanced compounds in this category, having progressed through multiple human clinical trials for mitochondrial disease.
Research-grade SS-31 is typically supplied as a lyophilized powder in sealed vials, commonly at 10mg to 50mg strengths, intended for laboratory research use.
SS-31 selectively binds cardiolipin, a phospholipid unique to the inner mitochondrial membrane, where it is studied for stabilizing mitochondrial cristae structure and improving electron-transport-chain efficiency — a distinct mechanism from peptides that act at cell-surface receptors.
SS-31 has been studied in human clinical trials for Barth syndrome, a rare genetic mitochondrial disorder, and in research on mitochondrial dysfunction more broadly, giving it a more developed clinical research record than most peptides in this category.
Beyond rare-disease research, SS-31 has been studied in models of heart failure and age-related mitochondrial decline, reflecting broader interest in cardiolipin-targeted therapeutics for conditions involving mitochondrial dysfunction.
As a clinically trialed compound, SS-31/Elamipretide has published human safety data from its trial programs, including reports of injection-site reactions; it has not, however, received full FDA approval for a marketed indication, and research-grade material outside those regulated trials has not undergone the same quality controls.
Doses used in published clinical trials are documented in that trial literature and are specific to those regulated study protocols; no FDA-approved commercial dosage exists for SS-31 research material.
Compound X does not sell SS-31 (Elamipretide) directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
SS-31/Elamipretide clinical trial data is indexed on PubMed under "Elamipretide SS-31 mitochondrial" and "Szeto-Schiller peptide cardiolipin."
New guides, vendor comparisons and compound breakdowns every week.